Prionoid Propagation of Protein Aggregates in Neurodegeneration

Prionoid Propagation of Protein Aggregates in Neurodegeneration

The prionoid propagation mechanism represents a unifying framework for understanding disease progression across multiple neurodegenerative proteinopathies. This pathway encompasses the template-directed misfolding and cell-to-cell transmission of pathological protein aggregates in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's disease (HD). Unlike classical prion diseases, these disorders are not infectious between individuals but share the fundamental property that misfolded proteins can "infect" neighboring cells and spread pathology through anatomically connected networks.

Template-Directed Misfolding as the Unifying Principle

Core Mechanism

The central principle underlying all prionoid propagation is template-directed misfolding (also termed "seeded aggregation" or "nucleated polymerization"). This process involves the templated conversion of normal, correctly folded proteins into pathological conformations by interaction with pre-existing misfolded aggregates[@prusiner2013][@frost2009].

The template-directed misfolding mechanism operates through several key steps:

Prionoid Propagation of Protein Aggregates in Neurodegeneration

The prionoid propagation mechanism represents a unifying framework for understanding disease progression across multiple neurodegenerative proteinopathies. This pathway encompasses the template-directed misfolding and cell-to-cell transmission of pathological protein aggregates in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's disease (HD). Unlike classical prion diseases, these disorders are not infectious between individuals but share the fundamental property that misfolded proteins can "infect" neighboring cells and spread pathology through anatomically connected networks.

Template-Directed Misfolding as the Unifying Principle

Core Mechanism

The central principle underlying all prionoid propagation is template-directed misfolding (also termed "seeded aggregation" or "nucleated polymerization"). This process involves the templated conversion of normal, correctly folded proteins into pathological conformations by interaction with pre-existing misfolded aggregates[@prusiner2013][@frost2009].

The template-directed misfolding mechanism operates through several key steps:

This mechanism fundamentally distinguishes prionoid diseases from conditions where protein accumulation occurs solely through increased production or decreased clearance[@jucker2013].

Common Features Across Diseases

All neurodegenerative disease-associated proteins that exhibit prionoid propagation share several structural and biochemical properties:

• β-sheet-rich fibrillar structure: Pathological aggregates adopt cross-β sheet conformations that are highly resistant to proteolytic degradation
• Ability to exist in multiple conformational states: The same protein can form distinct aggregate morphologies (strains) with different biological properties
• Seed competence: Aggregates can template the conversion of normally folded proteins into the pathological conformation
• Intercellular transfer capability: Pathological species can exit cells, travel through extracellular spaces, and enter neighboring cells

Strain Diversity in Protein Aggregates

Concept of Strains

The term "strain" refers to distinct conformational variants of the same protein that differ in their biological properties despite having identical amino acid sequences. This concept was first established in prion diseases but has since been extended to include tau, alpha-synuclein, TDP-43, and huntingtin aggregates[@sanders2014][@schubert2018].

Strain diversity arises from the ability of proteins to adopt multiple distinct amyloid folds. Each strain represents a different "self-propagating" conformation that can template its own conversion of normal protein. This has profound implications for:

• Disease phenotype variability
• Diagnostic biomarker development
• Therapeutic response heterogeneity

Tau Strains

Tau protein exhibits remarkable strain diversity that correlates with different clinical phenotypes[@fitzpatrick2017][@goedert2017]:

| Strain | Isoform Composition | Associated Diseases | Morphology |
|--------|---------------------|-------------------|------------|
| AD-type | 3R + 4R (mixed) | Alzheimer's disease | Paired helical filaments |
| CBD-type | 4R predominant | Corticobasal degeneration | Straight filaments |
| PSP-type | 4R predominant | Progressive supranuclear palsy | Straight filaments |
| AGD-type | 4R predominant | Argyrophilic grain disease | Short filaments |
| Pick-type | 3R predominant | Pick's disease | Round filaments |

Cryo-electron microscopy has revealed distinct atomic structures of tau filaments from different diseases, providing a structural basis for strain classification and explaining the phenotypic diversity of tauopathies[@fitzpatrick2017].

Alpha-Synuclein Strains

Alpha-synuclein forms multiple distinct aggregate strains that correspond to different clinical entities[@guo2013][@aulic2018]:

• Lewy body (LB) strain: Classic PD-associated strain, forms characteristic cytoplasmic inclusions
• Lewy body neurite (LBN) strain: Found in neuritic pathology, associated with more diffuse spread
• Multiple System Atrophy (MSA) strain: Highly aggressive strain causing oligodendroglial pathology

• Aggregation kinetics
• Cellular distribution patterns
• Seeding efficiencies
• Neurotoxicity profiles

TDP-43 Strains

TDP-43 protein aggregates in ALS and FTD also exhibit strain-like properties[@porta2018]:

• ALS-type strains: Characterized by cytoplasmic inclusions, associated with motor neuron disease
• FTD-type strains: More diffuse nuclear staining patterns, associated with behavioral variant FTD

Huntingtin Strains

Huntingtin protein (HTT) with expanded polyglutamine repeats forms aggregating species that also show strain diversity:

• Different conformations correlate with age of onset
• Aggregate morphology varies with repeat length
• Seeding properties differ between conformers

Cell-to-Cell Transmission Mechanisms

Exosome Release

Extracellular vesicles, particularly exosomes, represent a major pathway for intercellular transfer of pathological proteins[@wang2017][@stojkovska2018]:

Mechanism:

Disease-specific examples:

• Tau: Exosomal tau shows enhanced seeding activity compared to free tau[@wang2017]
• Alpha-synuclein: Exosome-associated alpha-synuclein is more resistant to degradation and more readily taken up by neurons[@stojkovska2018]
• TDP-43: Exosomal TDP-43 can transfer pathology between cells

Tunneling Nanotubes

Direct cell-to-cell connections called tunneling nanotubes (TNTs) provide another route for prionoid propagation[@costanzo2019][@abounit2015]:

Characteristics:

• F-actin-based membrane conduits connecting distant cells
• Enable direct cytoplasmic exchange
• Allow transfer of organelles, proteins, and aggregates
• Form between neurons, glia, and between neurons and astrocytes

• TNTs mediate tau transfer between neurons in culture[@costanzo2019]
• Alpha-synuclein propagates via TNTs between neurons and microglia[@abounit2015]
• TNT formation increases under cellular stress conditions

Lysosomal Exocytosis

Damaged lysosomes can release their contents through lysosomal exocytosis, providing another release pathway[@martinez2019]:

• Lysosomal membrane fusion with plasma membrane releases luminal content
• Pathological proteins accumulated in lysosomes can be released
• This mechanism is particularly relevant for proteins that undergo autophagy-lysosomal degradation

Direct Membrane Translocation

Some pathological proteins can directly translocate across cell membranes:

• Tau can enter cells through direct membrane translocation
• Alpha-synuclein exhibits cell-to-cell transfer without obvious vesicular intermediates
• This mechanism may involve transient membrane pores or protein-mediated transport

Spreading Patterns

Trans-Synaptic Spread (Tau)

Tau pathology follows a characteristic trans-synaptic spreading pattern[@auer2015][@calafate2015]:

The trans-synaptic spread of tau follows functional brain networks, explaining the predictable progression of pathology observed in AD[@calafate2015].

Retrograde and Anterograde Transport (Alpha-Synuclein)

Alpha-synuclein propagation follows both retrograde and anterograde pathways[@recasens2014][@valdinocci2017]:

Retrograde spread (from axon terminal to cell body):

• Follows the vagus nerve from the gut to the dorsal motor nucleus
• Accounts for the Braak hypothesis staging in PD
• Pathology spreads from peripheral nervous system to CNS

• Pathology moves along axonal projections
• Explains spread from substantia nigra to striatum
• Contributes to progressive motor impairment

Network-Based Propagation

All prionoid proteins follow brain connectivity patterns:

• Regions with strong functional connectivity to early pathology sites show later involvement
• White matter tract integrity predicts propagation rates
• Metabolic coupling between regions correlates with synchronized pathology accumulation

Cellular Uptake Mechanisms

Receptor-Mediated Endocytosis

Multiple receptors mediate the internalization of pathological proteins[@holmes2013][@benarroch2018]:

Heparan Sulfate Proteoglycans (HSPGs):

• Primary receptors for tau uptake[@holmes2013]
• Highly expressed on neuronal surfaces
• Mediate clathrin-dependent endocytosis of tau seeds
• Also facilitate alpha-synuclein and TDP-43 uptake

• Facilitates tau internalization
• Involved in alpha-synuclein uptake
• Activation can enhance or inhibit propagation depending on context

• Mediate uptake of antibody-opsonized proteins
• Relevant for understanding immunotherapy outcomes
• Activate microglia, potentially enhancing inflammatory responses

Pinocytosis

Non-specific pinocytosis also contributes to aggregate uptake:

• Fluid-phase endocytosis can capture extracellular aggregates
• Macropinocytosis may be induced by certain aggregate species
• This mechanism is less specific but provides an additional uptake pathway

Direct Membrane Fusion

In some cases, proteins can directly fuse with the plasma membrane:

• Exosome content can be delivered through membrane fusion
• Certain aggregate conformations may integrate directly into membranes

Strain Competition and Co-Aggregation

Strain Competition

When multiple protein strains are present, they can compete for the normal protein substrate[@roperto2019]:

• Faster aggregating strains may dominate
• Strain dominance can shift during disease progression
• Co-existence of multiple strains is common in human disease

Co-Aggregation

Different proteins can co-aggregate, creating mixed pathology[@bertelsen2021]:

• Tau and alpha-synuclein can co-aggregate in certain contexts
• TDP-43 can co-aggregate with other disease proteins
• Co-aggregation may influence disease progression and phenotype

Cross-Seeding

One protein aggregate can template the misfolding of a different protein:

• Alpha-synuclein can cross-seed tau
• Tau can cross-seed alpha-synuclein
• Cross-seeding may explain comorbidity between diseases

Therapeutic Strategies

Anti-Aggregation Compounds

Small molecules that prevent protein aggregation represent a key therapeutic approach[@soto2020][@javed2019]:

Mechanisms:

• Stabilize normal protein conformation
• Prevent nucleation and seed formation
• Disaggregate existing aggregates
• Enhance cellular clearance mechanisms

• Methylene blue derivatives (tau aggregation inhibitors)
• Epigallocatechin gallate (EGCG) - broad-spectrum anti-aggregant
• Curcumin and derivatives - aggregate-binding compounds
• Small molecule kinase inhibitors - reduce pathological phosphorylation

Antibody-Based Therapies

Immunotherapy targeting extracellular pathological proteins is actively being developed[@bae2019][@scialo2020]:

Passive Immunization:

• Monoclonal antibodies against tau, alpha-synuclein, TDP-43
• Antibodies designed to bind aggregate-specific conformations
• Focus on neutralizing extracellular seeds

• Vaccine approaches to induce endogenous antibody production
• Target pathological conformational epitopes
• Several candidates in clinical trials

• Neutralize extracellular aggregates
• Enhance Fc-mediated microglial clearance
• Prevent cellular uptake of seeds

Gene Therapy Approaches

Genetic interventions offer potential for disease modification[@scialo2020]:

• Antisense oligonucleotides (ASOs) to reduce protein expression
• CRISPR-based approaches to correct disease-causing mutations
• Viral vector delivery of protective genes
• RNA interference to silence specific protein expression

Combination Therapies

Given the complexity of prionoid propagation, combination approaches are likely to be most effective:

• Anti-aggregation + immunotherapy
• Multiple antibodies targeting different epitopes
• Clearance enhancement + aggregation inhibition
• Targeting release + uptake mechanisms

Comparative Mermaid Diagram

Cross-Linking to Related Mechanisms

Primary Cross-Links

• [Tau Spreading Mechanism](/mechanisms/tau-spreading) - Detailed tau propagation
• [Tau Seeding and Propagation Pathway](/mechanisms/tau-seeding-propagation-pathway) - Tau-specific seeding
• [Alpha-Synuclein Propagation](/mechanisms/alpha-synuclein-propagation) - Alpha-synuclein spread
• [Alpha-Synuclein Seeding Kinetics](/mechanisms/alpha-synuclein-seeding-kinetics) - Seeding mechanisms
• [Prion-Like Propagation in Neurodegeneration](/mechanisms/prion-like-propagation-neurodegeneration) - General prionoid concept
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) - TDP-43 aggregation

Disease Contexts

• [Alzheimer's Disease](/diseases/alzheimers-disease) - Primary tauopathy
• [Parkinson's Disease](/diseases/parkinsons-disease) - Alpha-synucleinopathy
• [ALS](/diseases/amyotrophic-lateral-sclerosis) - TDP-43 proteinopathy
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) - TDP-43 spectrum
• [Huntington's Disease](/diseases/huntingtons) - Polyglutamine disease

Related Mechanisms

• [Exosome-Mediated Propagation](/mechanisms/exosome-mediated-propagation) - Vesicular spread
• [Tunneling Nanotube Propagation](/mechanisms/tunneling-nanotube-propagation) - Direct cell-to-cell
• [Neuroinflammation](/mechanisms/neuroinflammation-microglia-astrocytes) - Glial responses
• [Protein Clearance Systems](/mechanisms/autophagy-ubiquitin-proteasome) - Cellular degradation

References